Aranesp Related Published Studies
Well-designed clinical trials related to Aranesp (Erythropoiesis Stimulating Protein)
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). [2009.07]
Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron. [2008.12]
Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. [2006.05]
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. [2005.03]
Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. [2001.08]
Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. [1999.11]
Optimal timing of repeated rh-erythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers. [1996.02]
Well-designed clinical trials possibly related to Aranesp (Erythropoiesis Stimulating Protein)
Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. [2009.09.03]
Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. [2009.09]
Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial). [2009.07.28]
Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. [2009.06]
Effects of Darbepoetin Alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. [2009.04.15]
HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. [2009.04]
Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. [2009.04]
Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa. [2009.02]
Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. [2009.02]
Erythropoietin Treatment in Patients with Chronic Heart Failure: a meta-analysis. [2009.01.23]
Effect of FX dialysers on systemic inflammation and quality of life in chronic haemodialysis patients. [2009]
Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. [2008.11]
Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. [2008.09.15]
Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: a randomized controlled trial. [2008.09]
Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. [2008.08.01]
Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. [2008.07]
ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data. [2008.07]
A trial comparing local pain after subcutaneous injection of epoetin-beta versus darbepoetin-alpha in healthy volunteers. [2008.07]
Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. [2008.06]
Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. [2008.05.10]
Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. [2008.05]
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. [2008.04.01]
Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. [2008.04.01]
Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. [2008.04]
Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. [2008.03.01]
Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. [2008.01.29]
Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa. [2007.12]
Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. [2007.12]
Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. [2007.11]
Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). [2007.10.20]
A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. [2007.10]
The effect of 4 wk of oral echinacea supplementation on serum erythropoietin and indices of erythropoietic status. [2007.08]
Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. [2007.06]
Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients. [2007.06]
A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia. [2007.06]
Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. [2007.05.01]
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. [2007.05]
The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. [2007.05]
Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. [2007.03]
Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy. [2007.03]
Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. [2007.03]
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. [2007.02.20]
Increased injection pain with darbepoetin-alpha compared to epoetin-beta in paediatric dialysis patients. [2006.12]
Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. [2006.12]
Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. [2006.11]
Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements--a randomized study. [2006.10]
Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. [2006.09.01]
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? [2006.07.01]
A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity. [2006.07]
Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. [2006.05.20]
Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. [2006.05]
Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. [2006.04]
Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. [2006.03]
Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. [2006.02.15]
Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial. [2006]
Effect of darbepoetin alfa on physical function in patients undergoing surgery for colorectal cancer. A randomized, double-blind, placebo-controlled study. [2006]
Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. [2005.12]
Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. [2005.10.01]
Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. [2005.08]
A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia. [2005.07]
Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. [2005.05]
Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. [2005.05]
Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. [2005.04]
Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. [2005]
Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. [2004.04]
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. [2004.02.15]
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. [2004]
Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. [2003.09]
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. [2003.03.01]
Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. [2003.03]
Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. [2002.12]
Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. [2002.11]
Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. [2002.11]
Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations. [2002.10]
Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. [2002.10]
Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. [2002.10]
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. [2002.08.21]
Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. [2002.07.29]
Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. [2002.07]
Hematopoietic growth factors for the treatment of myelodysplastic syndromes. [1998.02]
Continuous intravenous intradialysis versus intravenous postdialysis erythropoietin therapy in chronic haemodialysis patients: a randomized, controlled, crossover study. [1998.01]
Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. [1997.12]
Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group. [1997.04]
Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. [1996.04]
Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study. [1995.08.01]
Double blind trial of recombinant human erythropoietin in preterm infants. [1993.03]
Other research related to Aranesp (Erythropoiesis Stimulating Protein)
Lipopolysaccharide evokes resistance to erythropoiesis induced by the long-acting erythropoietin analogue darbepoetin alfa in rats. [2009.09]
Assessing the quality of prescribing and monitoring erythropoiesis-stimulating agents in the nursing home setting. [2009.07]
2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. [2009.07]
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. [2009.05.02]
Observational Aranesp Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa. [2009.02]
Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients. [2009.01]
Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naive to erythropoiesis-stimulating agents. [2009.01]
The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now? [2008.12]
|
